scholarly journals Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response

2017 ◽  
Vol 8 ◽  
Author(s):  
Robert Weissert ◽  
Fabienne Brilot
1999 ◽  
Vol 73 (3) ◽  
pp. 1795-1801 ◽  
Author(s):  
Diane M. P. Lawrence ◽  
Melinda M. Vaughn ◽  
Alec R. Belman ◽  
Joan S. Cole ◽  
Glenn F. Rall

ABSTRACT In many cases of neurological disease associated with viral infection, such as measles virus (MV)-induced subacute sclerosing panencephalitis in children, it is unclear whether the virus or the antiviral immune response within the brain is the cause of disease. MV inoculation of transgenic mice expressing the human MV receptor, CD46, exclusively in neurons resulted in neuronal infection and fatal encephalitis within 2 weeks in neonates, while mice older than 3 weeks of age were resistant to both infection and disease. At all ages, T lymphocytes infiltrated the brain in response to inoculation. To determine the role of lymphocytes in disease progression, CD46+ mice were back-crossed to T- and B-cell-deficient RAG-2 knockout mice. The lymphocyte deficiency did not affect the outcome of disease in neonates, but adult CD46+RAG-2− mice were much more susceptible to both neuronal infection and central nervous system disease than their immunocompetent littermates. These results indicate that CD46-dependent MV infection of neurons, rather than the antiviral immune response in the brain, produces neurological disease in this model system and that immunocompetent adult mice, but not immunologically compromised or immature mice, are protected from infection.


Author(s):  
Gudmundur Georgsson ◽  
Sigurbj�rg Torsteinsd�ttir ◽  
Gudmundur P�tursson ◽  
P�ll A. P�lsson ◽  
�lafur S. Andr�sson

2016 ◽  
Vol 65 (35) ◽  
pp. 930-933 ◽  
Author(s):  
Anita D. Sircar ◽  
Francisca Abanyie ◽  
Dean Blumberg ◽  
Peter Chin-Hong ◽  
Katrina S. Coulter ◽  
...  

2020 ◽  
Vol 60 (1) ◽  
pp. 291-309 ◽  
Author(s):  
Jesse A. Stokum ◽  
Volodymyr Gerzanich ◽  
Kevin N. Sheth ◽  
W. Taylor Kimberly ◽  
J. Marc Simard

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.


2021 ◽  
Vol 432 ◽  
pp. 213751
Author(s):  
Ke Chen ◽  
Si Sun ◽  
Junying Wang ◽  
Xiao-Dong Zhang

Sign in / Sign up

Export Citation Format

Share Document